ES2136581B1 - Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. - Google Patents

Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.

Info

Publication number
ES2136581B1
ES2136581B1 ES009801154A ES9801154A ES2136581B1 ES 2136581 B1 ES2136581 B1 ES 2136581B1 ES 009801154 A ES009801154 A ES 009801154A ES 9801154 A ES9801154 A ES 9801154A ES 2136581 B1 ES2136581 B1 ES 2136581B1
Authority
ES
Spain
Prior art keywords
preparation
transcription factor
derivatives
trifluorometilbenzoico
hidroxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009801154A
Other languages
English (en)
Spanish (es)
Other versions
ES2136581A1 (es
Inventor
Roca Manuel Merlos
De Arriba Alberto Fernandez
De Maria Fernando L Cavalcanti
Acosta Agusti Miralles
Crespo Mariano Sanchez
Rafanell Julian Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009801154A priority Critical patent/ES2136581B1/es
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Priority to DE69910019T priority patent/DE69910019T2/de
Priority to JP2000550490A priority patent/JP2002516283A/ja
Priority to EP99920872A priority patent/EP1082962B1/en
Priority to AU38286/99A priority patent/AU3828699A/en
Priority to DK99920872T priority patent/DK1082962T3/da
Priority to AT99920872T priority patent/ATE245987T1/de
Priority to PCT/ES1999/000154 priority patent/WO1999061030A1/es
Priority to ES99920872T priority patent/ES2204129T3/es
Priority to KR1020067026281A priority patent/KR100762156B1/ko
Priority to BR9911598-0A priority patent/BR9911598A/pt
Priority to EP03012255A priority patent/EP1362592A1/en
Priority to PT99920872T priority patent/PT1082962E/pt
Priority to US09/701,270 priority patent/US6414025B1/en
Priority to CA002332863A priority patent/CA2332863A1/en
Priority to KR1020007013316A priority patent/KR100713601B1/ko
Publication of ES2136581A1 publication Critical patent/ES2136581A1/es
Application granted granted Critical
Publication of ES2136581B1 publication Critical patent/ES2136581B1/es
Priority to NO20005981A priority patent/NO20005981L/no
Priority to US10/115,140 priority patent/US6610745B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES009801154A 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. Expired - Fee Related ES2136581B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
EP03012255A EP1362592A1 (en) 1998-05-27 1999-05-26 Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kB
EP99920872A EP1082962B1 (en) 1998-05-27 1999-05-26 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors nf-(k)b
AU38286/99A AU3828699A (en) 1998-05-27 1999-05-26 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitorsof the activation of the nuclear transcription factors nf-Kappa
DK99920872T DK1082962T3 (da) 1998-05-27 1999-05-26 Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B
AT99920872T ATE245987T1 (de) 1998-05-27 1999-05-26 Verwendung von derivaten der 2-hydroxy-4- trifluormethylbenzoe säure als hemmer der aktivierung des nuklearischen transkriptionsfaktors nf-(k)b
PCT/ES1999/000154 WO1999061030A1 (es) 1998-05-27 1999-05-26 USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB
ES99920872T ES2204129T3 (es) 1998-05-27 1999-05-26 Uso de derivados del acido 2-hidroxi-4-trifluorometilbenzoico como inhibidores de la activacion del factor de transcripcion nuclear nf- (k)b.
KR1020067026281A KR100762156B1 (ko) 1998-05-27 1999-05-26 핵전사인자 ＮＦ-κＢ의 활성화의 억제제로서의2-히드록시-4-트리플루오로메틸벤조산 유도체의 용도
US09/701,270 US6414025B1 (en) 1998-05-27 1999-05-26 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors NF-κβ
DE69910019T DE69910019T2 (de) 1998-05-27 1999-05-26 Verwendung von derivaten der 2-hydroxy-4-trifluormethylbenzoe säure als hemmer der aktivierung des nuklearischen transkriptionsfaktors nf-(k)b
JP2000550490A JP2002516283A (ja) 1998-05-27 1999-05-26 核転写因子ＮＦ−κＢの活性化の阻害剤としての２−ヒドロキシ−４−トリフルオロメチル安息香酸誘導体の使用
BR9911598-0A BR9911598A (pt) 1998-05-27 1999-05-26 Uso de derivados do ácido 2-hidróxi-4-trifluormetilbenzóico como inibidores da ativação do fator de transcrição nuclear nf-kb
CA002332863A CA2332863A1 (en) 1998-05-27 1999-05-26 Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor nf-.kappa.b
KR1020007013316A KR100713601B1 (ko) 1998-05-27 1999-05-26 핵전사인자 ＮＦ-κＢ의 활성화의 억제제로서의2-히드록시-4-트리플루오로메틸벤조산 유도체의 용도
PT99920872T PT1082962E (pt) 1998-05-27 1999-05-26 Utilizacao de derivados do acido 2-hidroxi-4-trifluorometilbenzoico como inibidores da activacao dos factores de transcricao nucleares nf-(k)b
NO20005981A NO20005981L (no) 1998-05-27 2000-11-27 Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B
US10/115,140 US6610745B2 (en) 1998-05-27 2002-04-04 Use of 2-hydroxy-4-trifluoromethyl-benzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-KS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.

Publications (2)

Publication Number Publication Date
ES2136581A1 ES2136581A1 (es) 1999-11-16
ES2136581B1 true ES2136581B1 (es) 2000-09-16

Family

ID=8304002

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801154A Expired - Fee Related ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
ES99920872T Expired - Lifetime ES2204129T3 (es) 1998-05-27 1999-05-26 Uso de derivados del acido 2-hidroxi-4-trifluorometilbenzoico como inhibidores de la activacion del factor de transcripcion nuclear nf- (k)b.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99920872T Expired - Lifetime ES2204129T3 (es) 1998-05-27 1999-05-26 Uso de derivados del acido 2-hidroxi-4-trifluorometilbenzoico como inhibidores de la activacion del factor de transcripcion nuclear nf- (k)b.

Country Status (14)

Country Link
US (2) US6414025B1 (https=)
EP (2) EP1082962B1 (https=)
JP (1) JP2002516283A (https=)
KR (2) KR100762156B1 (https=)
AT (1) ATE245987T1 (https=)
AU (1) AU3828699A (https=)
BR (1) BR9911598A (https=)
CA (1) CA2332863A1 (https=)
DE (1) DE69910019T2 (https=)
DK (1) DK1082962T3 (https=)
ES (2) ES2136581B1 (https=)
NO (1) NO20005981L (https=)
PT (1) PT1082962E (https=)
WO (1) WO1999061030A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154242B1 (es) * 1999-09-03 2001-10-16 Uriach & Cia Sa J Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb.
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
ES2190373B1 (es) * 2001-12-07 2004-10-16 J. URIACH &amp; CIA, S.A. Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
EP3656385A1 (en) 2008-05-28 2020-05-27 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
EP2556083A4 (en) 2010-04-05 2013-12-04 Validus Biopharma Inc NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT
CN103665012B (zh) * 2013-12-06 2016-06-22 辽宁师范大学 新型三氟柳无机药物化合物及合成方法
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US20180016314A1 (en) * 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
ES2886122T3 (es) * 2016-10-14 2021-12-16 Inst Pasteur De Montevideo Moduladores antinflamatorios y metabólicos pluripotentes para el tratamiento de afecciones relacionadas con la inflamación
KR101975603B1 (ko) 2018-09-14 2019-08-28 이영문 조력 발전장치
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096252A (en) * 1976-06-10 1978-06-20 J. Uriach & Cia S.A. 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria

Also Published As

Publication number Publication date
JP2002516283A (ja) 2002-06-04
NO20005981D0 (no) 2000-11-27
WO1999061030A1 (es) 1999-12-02
ATE245987T1 (de) 2003-08-15
US20030032630A1 (en) 2003-02-13
NO20005981L (no) 2000-12-12
AU3828699A (en) 1999-12-13
EP1082962B1 (en) 2003-07-30
KR100762156B1 (ko) 2007-10-04
KR20070006943A (ko) 2007-01-11
KR20010052404A (ko) 2001-06-25
DE69910019D1 (de) 2003-09-04
ES2136581A1 (es) 1999-11-16
BR9911598A (pt) 2001-02-13
EP1362592A1 (en) 2003-11-19
EP1082962A1 (en) 2001-03-14
DE69910019T2 (de) 2004-05-06
US6610745B2 (en) 2003-08-26
KR100713601B1 (ko) 2007-05-02
DK1082962T3 (da) 2003-11-24
PT1082962E (pt) 2003-11-28
US6414025B1 (en) 2002-07-02
CA2332863A1 (en) 1999-12-02
ES2204129T3 (es) 2004-04-16

Similar Documents

Publication Publication Date Title
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
ES2136581B1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
BR0116607A (pt) Derivados de glicopiranosiloxipirazol e uso dos mesmos em medicamentos
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
PL345923A1 (en) Cosmetic and pharmaceutic emulsions of oil-in-water type
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
SE0001899D0 (sv) New compounds
BR0015188A (pt) Composições farmacêuticas
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BR9908488A (pt) Composição farmacêutica de topiramato
DK1162982T3 (da) Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
ES2176106A1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
MX9704490A (es) Tratamiento terapeutico combinado de las patologias hiperproliferativas.
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
AR011860A1 (es) Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991116

Kind code of ref document: A1

Effective date: 19991116

FD1A Patent lapsed

Effective date: 20050528